(Q39323511)

30 June 2019

title

Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands (English)

1 reference

30 June 2019

1 reference

lymphoblastic leukemia

1 reference

3

1 reference

30 June 2019

Laura Jardine

1

object named as

Laura Jardine

1 reference

30 June 2019

author name string

Sophie Hambleton

2

1 reference

30 June 2019

Sarah Pagan

4

1 reference

30 June 2019

Xiao-Nong Wang

5

1 reference

30 June 2019

Matthew Collin

6

1 reference

30 June 2019

publication date

8 September 2012

1 reference

30 June 2019

published in

Leukemia & Lymphoma

1 reference

30 June 2019

volume

54

1 reference

30 June 2019

issue

1

1 reference

30 June 2019

page(s)

167-173

1 reference

30 June 2019

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Novel associations between activating killer-cell immunoglobulin-like receptor genes and childhood leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Approval summary for bortezomib for injection in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Concomitant administration of cholestyramine influences the absorption of troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

NKG2D-DAP10 triggers human NK cell–mediated killing via a Syk-independent regulatory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Histone deacetylase inhibitors suppress natural killer cell cytolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.708026

Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation.

21 January 2018

1 reference

12 December 2020

Pioglitazone inhibits the growth of human leukemia cell lines and primary leukemia cells while sparing normal hematopoietic stem cells.

1 reference

12 December 2020

Disposition of valproic acid in self-poisoned adults

1 reference

12 December 2020

Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells

1 reference

12 December 2020

10.3109/10428194.2012.708026

Identifiers

DOI

1 reference

30 June 2019

PMC publication ID

6588533

1 reference

30 June 2019

PubMed publication ID

22742576

1 reference

30 June 2019